



Atty. Dkt. No. 053466-0296

***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***

Applicant: Tadimitsu KISHIMOTO, et al.

Title: CHRONIC RHEUMATOID ARTHRITIS  
THERAPY CONTAINING IL-6 ANTAGONIST AS  
EFFECTIVE COMPONENT

Appl. No.: 09/756,125

Filing Date: 01/09/2001

Examiner: G. Ewoldt

Art Unit: 1644

**DECLARATION REGARDING AMENDATORY MATERIAL**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I, Todd N. Spalding, declare that:

1. I am a registered attorney duly authorized to prosecute the captioned application.
2. I have reviewed and understand the contents of the captioned application.
3. The application's specification has been amended to recite explicitly material that previously was incorporated by reference. More particularly, at the paragraph bridging pages 10-11, the specification cited WO 92/19759 for the disclosure of reshaped antibody hPM-1. By an amendment filed June 13, 2003, Applicants inserted into the specification an explicit description of reshaped antibody hPM-1 from WO 92/19759. Because the amendatory material was previously was incorporated by reference, its insertion did not add new matter into the application.

4. I further declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon, or any patent to which this declaration is directed.

Date 02/03/05

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 672-5569  
Facsimile: (202) 672-5399

  
\_\_\_\_\_

Todd N. Spalding  
Attorney for Applicant  
Registration No. 55,638